Pregabalin as a premedication for anxiety in patients undergoing plastic surgery: randomized double-blind, placebo-controlled study.

OBJECTIVE: To evaluate the usefulness of premedication with 75 mg pregabalin orally to reduce the degree of preoperative anxiety in patients scheduled for plastic surgery procedures. METHOD: A controlled randomized double-blind clinical trial that analyzed two groups of patients: 75 mg pregabalin tablet (Pg) against placebo tablet (Pl). Efficacy was assessed using the visual anxiety scale (VAS) with two measurements, the first without medication and the second 70 minutes after the drug was taken. RESULTS: One hundred patients were evaluated, fifty received pregabalin and fifty placebo, baseline VAS score showed an general average of 4.6 ± 1.9 points, significantly higher in the Pg group (Pg 5.2 ± 2.1 points vs 4.1 ± 1.6 points Pl; p = 0.0035). The VAS score after premedication was 3.9 ± 2.1 points, significantly lower in the Pg group (Pg 3.2 ± 1.6 points vs 4.6 ± 2.3 Pl points, p = 0.0006). CONCLUSION: Premedication 75 mg pregabalin orally decreases the degree of preoperative anxiety in adult patients scheduled for plastic surgery procedures.

OBJETIVO: Evaluar la utilidad de la premedicación con 75 mg de pregabalina por vía oral como dosis única para disminuir el grado de ansiedad preoperatoria en pacientes sometidos a cirugía plástica. MÉTODO: Ensayo clínico controlado, prospectivo, aleatorizado, doble ciego, que analizó dos grupos de pacientes: pregabalina tableta de 75 mg (grupo Pg) contra tableta placebo (grupo Pl). La eficacia se evaluó utilizando la escala visual de ansiedad (EVa) con dos mediciones, la primera sin medicación y la segunda 70 minutos después de tomar la cápsula. RESULTADOS: Se evaluaron 100 pacientes: 50 que recibieron pregabalina y 50 placebo. La puntuación basal de la EVa mostró un promedio general de 4.6 ± 1.9 puntos, significativamente mayor en el grupo Pg (5.2 ± 2.1 puntos en Pg vs. 4.1 ± 1.6 puntos en Pl; p = 0.0035). El puntaje en la EVa posterior a la premedicación fue de 3.9 ± 2.1 puntos, significativamente menor en el grupo Pg (3.2 ± 1.6 puntos en Pg vs. 4.6 ± 2.3 puntos en Pl; p = 0.0006). CONCLUSIÓN: La premedicación con 75 mg de pregabalina disminuye el grado de ansiedad preoperatoria en pacientes que serán intervenidos de cirugía plástica.

MS4A2-rs573790 Is Associated With Aspirin-Exacerbated Respiratory Disease: Replicative Study Using a Candidate Gene Strategy.

Aspirin exacerbated respiratory disease (AERD) is a set of diseases of the unified airway, and its physiopathology is related to disruption of the metabolism of arachidonic acid (AA). Genetic association studies in AERD had explored single nucleotide polymorphism (SNPs) in several genes related to many mechanisms (AA metabolism, inflammation, drug metabolism, etc.) but most lack validation stages in second populations. Our aim is to evaluated whether contribution to susceptibility of SNPs reported in other populations are associated with AERD in Mexican Mestizo patients. We developed a replicative study in two stages. In the first, 381 SNPs selected by fine mapping of associated genes, (previously reported in the literature), were integrated into a microarray and tested in three groups (AERD, asthma and healthy controls -HC-) using the GoldenGate array. Results associated to risk based on genetic models [comparing: AERD vs. HC (comparison 1, C1), AERD vs. asthma (C2), and asthma vs. HC (C3)] were validated in the second stage in other population groups using qPCR. In the first stage, we identified 11 SNPs associated with risk in C1.The top SNPs were ACE-rs4309C (p = 0.0001) and MS4A2-rs573790C (p = 0.0002). In C2, we detected 14 SNPs, including ACE-rs4309C (p = 0.0001). In C3, we found MS4A2-rs573790C (p = 0.001). Using genetic models, C1 MS4A2-rs57370 CC (p = 0.001), and ACE-rs4309 CC (p = 0.002) had associations. In C2 ACE-rs4309 CC (p = 0.0001) and C3 MS4A2-rs573790 CC (p = 0.001) were also associate with risk. In the second stage, only MS4A2-rs573790 CC had significance in C1 and C3 (p = 0.008 and p = 0.03). We concluded that rs573790 in the MS4A2 gene is the only SNP that supports an association with AERD in Mexican Mestizo patients in both stages of the study.